NextFin News - Smart ring maker Oura's initial public offering is drawing orders for roughly four times the shares on offer, a strong signal that investors are willing to pay a premium for a consumer-health story that has already reached profitability. The Finnish-founded company launched its roadshow at $40 to $44 a share, a range that values the business at as much as $15.62 billion on a fully diluted basis — about 42% above the $11 billion mark set in its October 2025 funding round, and barely eleven months earlier. The question the market will answer next week is whether Oura is a hardware company wearing a software multiple, or a recurring-revenue health-data franchise that happens to sell titanium.
The Deal: A Liquidity Event Disguised as a Fundraise
Oura Health launched its Nasdaq roadshow on September 21, 2026, offering 50 million shares under the ticker OURA with a debut targeted for the week of September 28 and pricing expected on September 29. At the top of the $40-to-$44 range, the company would command a market value of about $14.1 billion on outstanding shares, or $15.62 billion fully diluted. The deal could raise as much as $2.2 billion, but the headline number overstates how much capital actually lands on Oura's balance sheet.
Only 13.5 million of the 50 million shares are being sold by Oura itself. The other 36.5 million — 73% of the offering — are secondary shares sold by existing investors and employees. At the $42 midpoint, shareholders would collect roughly $1.53 billion while the company receives about $567 million before fees. Forerunner Ventures, the second-largest shareholder, is selling its entire 9.3% stake, about 28.7 million shares worth approximately $1.2 billion at the midpoint — nearly 80% of all the secondary stock on offer. Forerunner first backed Oura in the 2020 Series B round at a fraction of today's price.
The company's own use of proceeds underscores the point. Of the roughly $532.6 million in net proceeds it expects at the midpoint, about $526.4 million is earmarked to pay tax obligations tied to employee share grants that vest at the IPO. That leaves approximately $6.2 million for general corporate purposes. Oura is not raising growth capital; it is converting a decade of private appreciation into liquidity for early backers and settling a tax bill without touching its $372 million cash pile or drawing further on its $380 million of debt, of which $375 million is already pulled on a $525 million revolver.
That structure is the first thing a skeptical investor will seize on, and it is not an accident. A secondary-heavy IPO is the standard exit architecture for founder- and venture-backed companies of this size — but it means public investors are mostly buying out insiders at a 42% premium to a private round completed less than a year ago, while the company itself nets about $6 million for operations.
The Membership Engine Behind the Hardware
Oura's pitch rests on a simple premise: the ring is the customer-acquisition device; the membership is the business. Membership revenue grew 121% year over year to $240.5 million in the first nine months of fiscal 2026, nearly double the pace of the 74% total-revenue growth, and now accounts for about 20% of sales. The membership carries an 89% gross margin, versus roughly 46% on hardware, lifting the blended gross margin to 55% from 51%.
The retention math is what makes the membership story credible. Oura reports weighted-average twelve-month paid-member retention of about 85%, and the figure has climbed by cohort — 81% in fiscal 2023, 85% in fiscal 2024, 87% in fiscal 2025. Five million paid members as of June 30, 2026, up from 2.5 million a year earlier, with a daily-to-monthly active-user ratio of about 65% and a median daily wear time of 23 hours, describe a product that stays on the customer's body. Repeat ring purchases accounted for 11% of units sold in the nine months ended June 2026, up from 9% in fiscal 2025 and 5% in fiscal 2024 — evidence that the installed base refreshes rather than churns.
But the framing matters. Hardware still generated $974 million, or about 80% of revenue, in the first nine months. A company that is four-fifths hardware does not trade like software, no matter how sticky the subscription. The valuation Oura is seeking depends on investors believing the membership mix keeps compounding toward software-like economics while the ring remains a differentiated, defensible device. Chief Executive Tom Hale has framed the company accordingly, saying in a company statement: "We've earned the trust of millions of people around the world to help them understand some of their most personal health signals."
We've evolved beyond tracking to deliver actionable health intelligence that helps people better understand our bodies and make more informed decisions for our long-term health.
The demographic profile supports the platform argument. Approximately 72% of Oura's members are women, and female membership has grown at a compound annual rate of roughly 143% since fiscal 2024, against 94% for male members. More than half of all members report at least one chronic health condition, and 80% of those say they use Oura data to inform decisions about it; 15% of U.S. members work in healthcare. That is not the profile of a fitness-gadget buyer — it is the profile of someone managing a health condition.
The Valuation: Disciplined Against Peers, Rich Against History
At the $42 midpoint, Oura trades at roughly 9.7 times annualized sales based on its latest nine-month run rate. That sits above Garmin's roughly 7.5 times sales but below Apple's roughly 12 times, a positioning that deliberately straddles consumer electronics and diversified technology. Measured against the $15.62 billion fully diluted target and approximately $1 billion of fiscal 2025 revenue, the implied multiple is about 15 times sales.
That is meaningfully cheaper than the wearables category's most recent private-market print. Whoop raised $575 million in March 2026 at a $10.1 billion valuation on roughly $260 million of 2025 revenue — an implied multiple near 39 times. On that comparison, Oura is pricing with public-market discipline. The uncomfortable counterpoint is that Whoop has not yet been tested by public investors, and Oura's own private mark has already jumped 42% in eleven months. A 15-times multiple is not demanding for a company growing revenue at 74% and printing positive net income, but it is a premium to the hardware peers it most closely resembles on revenue mix.
The profitability claim also requires a footnote. Oura reported $60.8 million of net income for the first nine months of fiscal 2026 and $106.7 million of adjusted EBITDA, up from $83.5 million a year earlier. But the net loss attributable to common stockholders for the same period was $924.3 million, widened from $182.8 million. That loss reflects a $985 million deemed dividend paid to holders of redeemable convertible preferred stock — an accounting entry tied to the pre-IPO capital structure rather than an operating loss, but one that will sit prominently on the face of the prospectus and give bears an easy headline.
The Second-Order Bet: A Data Layer for the Weight-Loss-Drug Era
The less obvious driver of demand is what happens when a biometric ring becomes infrastructure for the weight-loss-drug era. Eli Lilly has indicated interest in buying up to $100 million of shares in the offering, and Dragoneer Investment Group up to $300 million. Lilly already partners with Oura through its LillyDirect channel, integrating biometric tracking for patients on GLP-1 therapies, and Oura has integrated continuous glucose data from Dexcom's Stelo sensor into its app. A SAFE held by Lilly converts to common stock at listing.
The second-order implication is that Oura is selling itself as a measurement layer for metabolic health, not a fitness tracker. As millions of patients begin GLP-1 treatments for diabetes and weight management, clinicians face a practical problem: observing continuous physiological responses outside the clinic. A ring that records 23 hours a day of heart rate, sleep, and recovery data becomes a remote-monitoring asset — and remote monitoring is a reimbursable workflow, not a discretionary consumer purchase. That is the structural bet embedded in a 15-times multiple: not that more people will buy rings, but that the ring becomes the stethoscope of metabolic medicine.
This is where the cyclical-versus-structural call sharpens. The hardware leg of the business is cyclical: ring sales rise and fall with consumer discretionary spending, holiday seasons, and competitive launches, and they will mean-revert with the consumer cycle. The membership leg is more structural: once a member is enrolled, the 85% retention rate and the compounding value of longitudinal health data create a recurring revenue stream that does not self-correct downward on its own. The clinical-integration leg is the most structural of all — if payers or providers begin to rely on Oura data for treatment decisions, that revenue is locked in by workflow, not by consumer taste. The bull case requires all three legs to hold; the bear case only needs the first to break.
The Strongest Counter-Thesis
The bear case is straightforward and rests on three pillars. First, 73% of this IPO is secondary — public investors are mostly buying out insiders at a 42% premium to a private round completed less than a year ago, while the company itself nets about $6 million for operations. Second, the $924.3 million net loss attributable to common stockholders is a real overhang on the headline, even though it reflects a deemed dividend rather than an operating loss. Third, hardware demand is cyclical and competitive: Samsung's Galaxy Ring entered the market at the same $399 entry price, and Oura has defended its lead through litigation, filing patent disputes that have kept Ultrahuman and Luna rings blocked from U.S. sale and left Samsung's Galaxy Ring and Amazfit's Helio Ring in ongoing legal limbo. When Hale was asked about Samsung's entry, his public line was that the company welcomes "the competition and validation" — diplomatic, but an admission that the moat is no longer uncontested.
The counter-thesis is strongest on the secondary split, and it deserves its weight. But it also proves too much: nearly every founder- and venture-backed IPO of this size is predominantly secondary, and the market prices that through the discount it demands on day one, not by refusing to buy. The more decisive question is whether the membership leg of revenue can keep growing at twice the rate of hardware while gross margin holds near 55% — because that is what separates a 15-times multiple from a 7-times one.
The falsifying signal is specific and observable: if twelve-month paid-member retention falls below 80% for two consecutive quarters, or if membership revenue growth slows below hardware revenue growth for two consecutive quarters, the software-premium thesis breaks and the stock should reprice toward hardware multiples near Garmin's 7.5 times sales. Retention is the single metric that carries the entire valuation bridge.
What Comes Next
In the short term, a four-times-oversubscribed book and anchor commitments from Lilly and Dragoneer should support a firm print, likely at or near the top of the $40-to-$44 range. The first test comes on the opening print: a debut above $44 would signal appetite for the wearables category broadly, not just Oura; a break below the range would say the market is discounting the secondary-heavy structure and the hardware concentration. The listing lands inside a fall 2026 IPO window that bankers are working to reopen after a subdued start, and Oura is the first of a cluster of wearable and fitness companies — Strava and Whoop have signaled their own listings — to put a number on the public market.
Over the medium term, the quarters that matter are the ones that show membership revenue compounding faster than ring shipments while gross margin holds near 55%. Oura expects to end fiscal 2026 on September 30 with about 5.7 million paying members, nearly double the prior year, and the first public quarterly reports will confirm whether that trajectory survives the transition to public-market scrutiny. Investors should also watch the warranty and returns reserves, which have climbed — warranty liabilities reached $132 million as of June 2026, up from $98 million nine months earlier, and the returns reserve more than doubled to $88 million — as a tell on hardware quality and demand.
Over the long term, the structural question is whether Oura becomes a data layer for metabolic healthcare or remains a premium consumer device. The base case is a successful listing at a premium print followed by volatile but upward-drifting trading as the membership mix expands. The upside case is clinical integration — GLP-1 monitoring, glucose correlation, insurer or employer reimbursement — that re-rates the stock toward software multiples. The downside case is a sleep-accuracy ruling, a hardware demand slowdown, or retention slipping below 80%, any of which would compress the multiple toward consumer-electronics peers.
Oura's IPO is not really about smart rings. It is a test of whether the market will pay a software price for a company that still sells hardware — and whether a Finnish ring can become the stethoscope of the weight-loss-drug era.
Explore more exclusive insights at nextfin.ai.
